Cargando…

Methods for reducing delays in the diagnosis of multiple myeloma

Detalles Bibliográficos
Autor principal:	Koshiaris, Constantinos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Future Medicine Ltd 2019
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6410016/ https://www.ncbi.nlm.nih.gov/pubmed/30863530 http://dx.doi.org/10.2217/ijh-2018-0014

Ejemplares similares

Quantifying intervals to diagnosis in myeloma: a systematic review and meta-analysis
por: Koshiaris, Constantinos, et al.
Publicado: (2018)

Delayed Diagnosis of Cardiac Amyloidosis Secondary to Multiple Myeloma
por: Qatanani, Ahmad, et al.
Publicado: (2021)

Early detection of multiple myeloma in primary care using blood tests: a case–control study in primary care
por: Koshiaris, Constantinos, et al.
Publicado: (2018)

Immunotherapy for Multiple Myeloma
por: Kröger, Nicolaus, et al.
Publicado: (2012)

Hyperhaploid karyotypes in multiple myeloma
por: Sawyer, Jeffrey R., et al.
Publicado: (2017)

Novel therapies for multiple myeloma
por: Wallington-Beddoe, Craig T., et al.
Publicado: (2017)

Latest Development in Multiple Myeloma
por: Imai, Yoichi
Publicado: (2020)

Introduction to “Immunotherapies for Multiple Myeloma”
por: Offidani, Massimo, et al.
Publicado: (2020)

Immunomodulatory Agents for Multiple Myeloma
por: Minařík, Jiří, et al.
Publicado: (2022)

Cancer drug resistance in multiple myeloma
por: Uckun, Fatih M.
Publicado: (2022)

To be or not to be: the role of CD56 in multiple myeloma
por: Cottini, Francesca, et al.
Publicado: (2023)

Multiple mechanisms can disrupt oncogenic pathways in multiple myeloma
por: Hoang, Phuc H., et al.
Publicado: (2018)

Lenalidomide in the Treatment of Lymphoproliferative Disorders and Multiple Myeloma
por: Liberati, Anna Marina, et al.
Publicado: (2013)

Circulating tumour DNA analysis in multiple myeloma
por: Mithraprabhu, Sridurga, et al.
Publicado: (2017)

Recent Advances on the Pathobiology and Treatment of Multiple Myeloma
por: Amodio, Nicola
Publicado: (2021)

Immunotherapy for multiple myeloma: new chances and hope
por: Xu, Jingyu, et al.
Publicado: (2023)

Delayed diagnosis resulting in increased disease burden in multiple myeloma: the legacy of the COVID-19 pandemic
por: Carmichael, Jonathan, et al.
Publicado: (2023)

The Clinical Diagnosis of Multiple Myeloma
por: Ainley, N. J.
Publicado: (1954)

Diagnosis and therapy of multiple myeloma
por: Palumbo, Antonio, et al.
Publicado: (2013)

MRD in multiple myeloma: more questions than answers?
por: Moreau, Philippe, et al.
Publicado: (2017)

Optimizing therapy for del(17p) multiple myeloma
por: Avet-Loiseau, Hervé, et al.
Publicado: (2017)

The genomic features associated with high-risk multiple myeloma
por: Walker, Brian A., et al.
Publicado: (2018)

The Road to a Cure: Emerging Treatments for Multiple Myeloma
por: Caers, Jo
Publicado: (2020)

MRD negativity: considerations for older adults with multiple myeloma
por: Mian, Hira, et al.
Publicado: (2023)

Clinical prediction tools to identify patients at highest risk of myeloma in primary care: a retrospective open cohort study
por: Koshiaris, Constantinos, et al.
Publicado: (2021)

Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
por: Zhou, Jianbiao, et al.
Publicado: (2019)

Prognostic impact of Ikaros expression in lenalidomide-treated multiple myeloma
por: Krönke, Jan, et al.
Publicado: (2017)

Imaging in multiple myeloma: Computed tomography or magnetic resonance imaging?
por: Tagliafico, Alberto Stefano
Publicado: (2021)

The hope for targeting fatty acid binding proteins in multiple myeloma
por: Fairfield, Heather, et al.
Publicado: (2023)

Proptosis with hemiplegia: Unusual presentation of multiple myeloma
por: Ghosh, K
Publicado: (2018)

Early Diagnosis and Diagnostic Delay in Oral Cancer
por: Varela-Centelles, Pablo
Publicado: (2022)

Diagnosing myeloma in general practice: how might earlier diagnosis be achieved?
por: Smith, Lesley, et al.
Publicado: (2022)

New Perspectives Offered by Nuclear Medicine for the Imaging and Therapy of Multiple Myeloma
por: Mesguich, Charles, et al.
Publicado: (2016)

RNA processing: a new player of genomic instability in multiple myeloma
por: Marchesini, Matteo, et al.
Publicado: (2017)

Trogocytosis represents a novel mechanism of action of daratumumab in multiple myeloma
por: Krejcik, Jakub, et al.
Publicado: (2018)

CAR T-cell treatment of high-risk multiple myeloma: will there be a cure?
por: Gahrton, Gösta
Publicado: (2023)

The cellular architecture of multiple myeloma
por: Vicente-Dueñas, Carolina, et al.
Publicado: (2012)

Utility of repeating bone marrow biopsy for confirmation of complete response in multiple myeloma
por: Tschautscher, Marcella A., et al.
Publicado: (2020)

Anti-BCMA CAR T-cell Therapy: Changing the Natural History of Multiple Myeloma
por: Puertas, Borja, et al.
Publicado: (2022)

CAR T-cell therapy for triple-class exposed relapsed/refractory multiple myeloma
por: Cavo, Michele
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_rfk7u6jmjp33798tq42vif6bui